Bigul

Natco Pharma gets 9 observations from US drugs regulator for Kothur plant

The Food and Drug Administration's observations were procedural and "can be addressed within a short period of time", says Natco.
06-06-2019
Bigul

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

USFDA COMPLETES INSPECTION OF NATCO's KOTHUR FORMULATION FACILITY
06-06-2019
Bigul

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Natco files ANDA for Bosentan 32mg Tablets for the USA market
04-06-2019
Bigul

Natco Pharma: Pact with Onyx bodes well

Shares of Natco Pharma may remain in focus, as it has reached a settlement with Onyx Therapeutics, Inc on patent litigation related to generic version
30-05-2019
Bigul

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

NATCO settles generic Carfilzomib Injection Patent Litigation in the US market
30-05-2019
Bigul

Natco Pharma Ltd - 524816 - Reg.24(A)-Annual Secretarial Compliance

Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 01/04/2018 2Date of Report31/03/2019 3 Name of the Certifying Firm BK & Associates 4 Name of the Certifying Individual B Kiran Kumar 5Membership TypeACS 6 Membership Number 29116 7 CP No. 15876 8 Whether any observations/qualification reported by the Secretarial Auditor ? NO
28-05-2019
Bigul

Natco Pharma slips 8% on weak Q4 results; stock hits new low

The company's consolidated net profit more-than-halved at Rs 120 crore in March quarter against Rs 300 crore in the year-ago quarter.
28-05-2019
Bigul

Natco Pharma Ltd - 524816 - Record Date Fixed As 7Th June, 2019 For Payment Of Third Interim Dividend

Record date fixed as 7th June, 2019 for Payment of third Interim Dividend
27-05-2019
Bigul

NATCO PHARMA LTD. - 524816 - Results For The Financial Year 18-19

Results For the Financial Year 18-19
27-05-2019
Next Page
Close

Let's Open Free Demat Account